Filing Details

Accession Number:
0001053369-13-000003
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-01-14 18:49:34
Reporting Period:
2013-01-11
Filing Date:
2013-01-14
Accepted Time:
2013-01-14 18:49:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1053369 Elite Pharmaceuticals Inc ELTP Pharmaceutical Preparations (2834) 223542636
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1465825 G Ashok Nigalaye C/O Epic Pharma, Llc
227-15 North Conduit Avenue
Laurelton NY 11413
Chief Scientific Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2013-01-11 2,339,000 $0.09 7,628,584 No 4 S Indirect see footnote
Common Stock Acquisiton 2013-01-14 6,032,000 $0.06 13,660,584 No 4 M Indirect see footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect see footnote
No 4 M Indirect see footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant Disposition 2013-01-14 6,032,000 $0.06 6,032,000 $0.06
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,103,332 2009-06-03 2016-06-03 No 4 X Indirect
Footnotes
  1. Ashok G. Nigalaye is an equity owner and executive officer of each of Epic Pharma, LLC ("EP"), and Epic Investments, LLC ("EI") (which is controlled by EP), which owns securities convertible into or exercisable for in excess of 10% of the outstanding shares of common stock of the issuer, and also serves as a director of the issuer.
  2. Of the 7,628,584 shares of common stock, 6,989,002 shares of common stock are owned indirectly through EI and 639,582 shares are owned directly by the reporting person.
  3. Of the 13,660,584 shares of common stock, 13,021,002 shares of common stock are owned indirectly through EI and 639,582 shares are owned directly by the reporting person.